We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are developing CARMA, our proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges.
We understand and scientifically solve partners’ challenges by applying our expertise and proven delivery platform for cell-engineering.
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use more cost-effectively and with lowered risk.
Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and broad freedom to operate.
Scientists are just beginning to unravel the complexities of cells, their regulation, and their relationship to disease. As our understanding continues to grow, it reveals new avenues for therapeutic interventions and curative efforts.
Cell-engineering looks to unlock the power of cells for a variety of applications including the discovery, development and manufacture of novel small molecule drugs and biologics, the biomanufacturing of vaccines and biotherapeutics, the re-direction or enhancement of cells for use as cellular therapies and the modification of targeted genes in cells for therapeutic purposes through genomic editing.
We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation™ Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients. Flow
Electroporation Technology leverages a fundamental property of cells – the reversible permeability of membranes in the presence of an electrical charge – to create a transformative method for universally delivering molecules such as nucleic acids and proteins into cells, turning cells into drugs, etc.
Unlike other methods, Flow Electroporation Technology is a fully scalable, delivery platform that enables small-scale R&D through large-scale cell-engineering for global patient treatment. It is the leading non-viral delivery platform for cell-engineering in clinical use with an approved commercial immunotherapy in Japan and is currently being used in 10+ clinical trials.
We pair our high-performance delivery platform with our cell-engineering expertise to accelerate the discovery, development and manufacturing of next-generation, cell-based medicines – overcoming client challenges and enabling previously unfeasible cell-engineering applications.
As a company, we are dedicated to advancing cell-engineering through application of its patented delivery platform and collaborative partnerships. We are uniquely positioned at the center of cell therapy and gene editing: able to unlock the full power of the human cell to maximize the potential of these promising modalities.
Now is the time to speak up. At MaxCyte, we denounce racism, inequality, violence, coercion and discrimination in all forms.
At MaxCyte, we are committed to fostering workplace development, diversity, and inclusion (WDDI) within our own organization and across the biotechnology industry. We are dedicated to being at the forefront of efforts to develop a diverse and talented global workforce, and understand the value that diversity contributes to the culture and success of any business. Diverse teams enhance collaboration, are more accepting of differences, and are also more effective in the global environment in which we operate, enabling the promise of next-generation cell and gene-editing therapies around the globe.
To that end, we affirmatively support the WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, patients and the communities where we operate.
We acknowledge as a company that we must hold true to our values and treat each other with acceptance, care and respect — and we must hold one another accountable. We must speak up when we see examples of racism, discrimination, and violence — and we must help break down barriers. Now is the time to speak up. Now is the time to engage.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter